Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid

03 Mar 2021

Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.

Female athletes running towards finish line on track field — Ovid will let Takeda take soticlestat to the finish line

Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics, Inc. said they are revising their 2017 partnership to address severe pediatric epilepsies on 3 March, with a new agreement that gives the Japanese pharma full development and commercial rights to Phase III-ready soticlestat, while Ovid avoids significant R&D spending commitments and monetizes its share of the drug candidate. Takeda plans to launch Phase III trials of soticlestat in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) during the second quarter of 2021.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Sanofi Gains €10bn From Opella Sale

02 May 2025

• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

30 Apr 2025

• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

30 Apr 2025

• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.